Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2026-01-06 @ 12:23 AM
Study NCT ID:
NCT03259633
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2020-05-01
First Post:
2017-08-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2017-08-21
First Submit QC Date:
None
Study First Post Date:
2017-08-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-04-30
Last Update Post Date:
2020-05-01
Last Update Post Date Type:
ACTUAL